X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-01-17 | ADAP | Adaptimmune Therapeutics Plc | Norry Elliot | Chief Medical Officer | S - Sale | $0.58 | -5,584 | 7,510 | -43% | -$3,243 | ||||||
2025-01-17 | ADAP | Adaptimmune Therapeutics Plc | Lunger John | Chief Patient Supply Officer | S - Sale | $0.58 | -5,584 | 7,510 | -43% | -$3,243 | ||||||
2025-01-17 | ADAP | Adaptimmune Therapeutics Plc | Bertrand William C Jr | COO | S - Sale | $0.58 | -5,584 | 7,510 | -43% | -$3,243 | ||||||
2025-01-17 | ADAP | Adaptimmune Therapeutics Plc | Rawcliffe Adrian | CEO | S - Sale | $0.58 | -30,601 | 44,327 | -41% | -$17,773 | ||||||
| D | 2025-01-15 | NBIX | Neurocrine Biosciences Inc | Gano Kyle | CEO | S - Sale+OE | $141.50 | -65,000 | 135,392 | -32% | -$9,197,550 | |||||
2025-01-15 | CADL | Candel Therapeutics, Inc. | Barone Francesca | Chief Scientific Officer | S - Sale | $7.23 | -13,534 | 110,673 | -11% | -$97,783 | ||||||
2025-01-15 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $7.23 | -14,322 | 96,790 | -13% | -$103,476 | ||||||
2025-01-15 | CADL | Candel Therapeutics, Inc. | Schoch Charles | See Remarks | S - Sale | $7.23 | -9,511 | 43,038 | -18% | -$68,717 | ||||||
2025-01-15 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO | S - Sale | $7.23 | -21,704 | 251,912 | -8% | -$156,811 | ||||||
2025-01-15 | CADL | Candel Therapeutics, Inc. | Nichols William Garrett | Chief Medical Officer | S - Sale | $7.23 | -10,428 | 79,320 | -12% | -$75,342 | ||||||
2025-01-15 | IMVT | Immunovant, Inc. | Macias William L. | Chief Medical Officer | S - Sale | $23.83 | -2,383 | 359,408 | -1% | -$56,782 | ||||||
2025-01-15 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $23.83 | -2,298 | 324,766 | -1% | -$54,757 | ||||||
| D | 2025-01-15 | PCVX | Vaxcyte, Inc. | Loxam Teri | Dir | S - Sale+OE | $85.11 | -6,250 | 7,175 | -47% | -$531,963 | |||||
2025-01-15 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $23.83 | -8,767 | 964,225 | -1% | -$208,900 | ||||||
2025-01-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $91.35 | -2,500 | 129,873 | -2% | -$228,375 | ||||||
| M | 2025-01-13 | ADAP | Adaptimmune Therapeutics Plc | Rawcliffe Adrian | CEO | S - Sale | $0.58 | -59,569 | 41,582 | -59% | -$34,639 | |||||
2025-01-15 | ADAP | Adaptimmune Therapeutics Plc | Piccina Cintia | Chief Commercial Officer | S - Sale | $0.57 | -12,991 | 18,421 | -41% | -$7,467 | ||||||
2025-01-14 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $5.09 | -3,087 | 109,241 | -3% | -$15,713 | ||||||
2025-01-14 | VYGR | Voyager Therapeutics, Inc. | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $5.13 | -1,191 | 86,436 | -1% | -$6,110 | ||||||
| M | 2025-01-13 | ADAP | Adaptimmune Therapeutics Plc | Norry Elliot | Chief Medical Officer | S - Sale | $0.58 | -22,195 | 13,756 | -62% | -$12,920 | |||||
| M | 2025-01-13 | ADAP | Adaptimmune Therapeutics Plc | Lunger John | Chief Patient Supply Officer | S - Sale | $0.58 | -19,542 | 13,756 | -59% | -$11,360 | |||||
| M | 2025-01-13 | ADAP | Adaptimmune Therapeutics Plc | Bertrand William C Jr | COO | S - Sale | $0.58 | -19,542 | 13,756 | -59% | -$11,360 | |||||
| D | 2025-01-14 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $65.87 | -1,500 | 0 | -100% | -$98,801 | |||||
| M | 2025-01-10 | PASG | Passage Bio, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $0.64 | -223,219 | 7,034,626 | -3% | -$142,223 | |||||
| D | 2025-01-13 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $29.66 | -1,000 | 0 | -100% | -$29,660 | |||||
2025-01-10 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $43.26 | -5,886 | 110,096 | -5% | -$254,646 | ||||||
| D | 2025-01-10 | SLDB | Solid Biosciences Inc. | Tan Kevin | CFO, Treasurer | S - Sale+OE | $3.89 | -4,073 | 24,789 | -14% | -$15,849 | |||||
| DM | 2025-01-08 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $7.18 | -40,000 | 736,633 | -5% | -$287,200 | |||||
2025-01-10 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.44 | -409 | 499,889 | 0% | -$180 | ||||||
2025-01-10 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.44 | -332 | 68,174 | 0% | -$146 | ||||||
2025-01-10 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.44 | -979 | 17,814,681 | 0% | -$431 | ||||||
2025-01-10 | FATE | Fate Therapeutics Inc | Bressi Jerome Charles | See Remarks | S - Sale | $1.55 | -5,980 | 270,203 | -2% | -$9,269 | ||||||
2025-01-10 | FATE | Fate Therapeutics Inc | Tahl Cindy | See Remarks | S - Sale | $1.55 | -5,654 | 336,707 | -2% | -$8,764 | ||||||
2025-01-10 | FATE | Fate Therapeutics Inc | Valamehr Bahram | Pres, CEO | S - Sale | $1.54 | -8,705 | 349,364 | -2% | -$13,406 | ||||||
| DM | 2025-01-07 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $74.69 | -7,783 | 25,085 | -24% | -$581,316 | |||||
| DM | 2025-01-07 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale+OE | $75.24 | -18,009 | 9,582 | -65% | -$1,355,024 | |||||
| DM | 2025-01-07 | ACLX | Arcellx, Inc. | Elghandour Rami | SEE REMARKS | S - Sale+OE | $74.69 | -30,311 | 117,275 | -21% | -$2,263,942 | |||||
| ADM | 2025-01-03 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $78.36 | -5,950 | 32,868 | -15% | -$466,227 | |||||
| ADM | 2025-01-03 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale+OE | $78.36 | -11,243 | 27,591 | -29% | -$880,974 | |||||
| ADM | 2025-01-03 | ACLX | Arcellx, Inc. | Elghandour Rami | SEE REMARKS | S - Sale+OE | $78.36 | -30,223 | 147,586 | -17% | -$2,368,198 | |||||
| DM | 2025-01-07 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale+OE | $6.43 | -47,500 | 1,383,441 | -3% | -$305,343 | |||||
2025-01-08 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $48.85 | -15,000 | 1,309,487 | -1% | -$732,693 | ||||||
2025-01-08 | CADL | Candel Therapeutics, Inc. | Barone Francesca | Chief Scientific Officer | S - Sale | $8.22 | -13,673 | 124,207 | -10% | -$112,367 | ||||||
2025-01-08 | CADL | Candel Therapeutics, Inc. | Schoch Charles | See Remarks | S - Sale | $8.22 | -9,971 | 52,549 | -16% | -$81,944 | ||||||
2025-01-08 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO | S - Sale | $8.22 | -21,172 | 273,616 | -7% | -$173,996 | ||||||
2025-01-08 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $8.22 | -14,545 | 111,112 | -12% | -$119,534 | ||||||
2025-01-08 | CADL | Candel Therapeutics, Inc. | Nichols William Garrett | Chief Medical Officer | S - Sale | $8.22 | -10,799 | 89,748 | -11% | -$88,749 | ||||||
2025-01-08 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $24.10 | -4,105 | 327,064 | -1% | -$98,931 | ||||||
2025-01-08 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $24.10 | -5,105 | 972,992 | -1% | -$123,031 | ||||||
2025-01-07 | TWST | Twist Bioscience Corp | Chess Robert | Dir | S - Sale | $50.00 | -5,000 | 59,169 | -8% | -$250,000 | ||||||
2025-01-08 | SANA | Sana Biotechnology, Inc. | Fmr LLC | See Remark 1, 10% | S - Sale | $6.49 | -290,912 | 4,541,572 | -6% | -$1,887,320 | ||||||
| M | 2025-01-06 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale | $20.33 | -15,162 | 383,892 | -4% | -$308,291 | |||||
| M | 2025-01-06 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COFO, Secretary | S - Sale | $20.33 | -15,162 | 768,057 | -2% | -$308,291 | |||||
| M | 2025-01-06 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $20.34 | -36,916 | 2,455,675 | -1% | -$750,955 | |||||
2025-01-07 | DNLI | Denali Therapeutics Inc. | Krognes Steve E. | Dir | S - Sale | $20.81 | -3,339 | 807,554 | 0% | -$69,485 | ||||||
2025-01-08 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $12.52 | -10,960 | 1,312,391 | -1% | -$137,219 | ||||||
| M | 2025-01-06 | PASG | Passage Bio, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $0.70 | -147,024 | 7,257,845 | -2% | -$103,306 | |||||
| D | 2025-01-06 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $11.72 | -324 | 7,288 | -4% | -$3,797 | |||||
| D | 2025-01-06 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $11.72 | -645 | 33,216 | -2% | -$7,558 | |||||
2025-01-06 | BLUE | Bluebird Bio, Inc. | Colvin Richard A | Chief Medical Officer | S - Sale | $9.24 | -19 | 8,257 | 0% | -$176 | ||||||
2025-01-06 | BLUE | Bluebird Bio, Inc. | Obenshain Andrew | Pres, CEO | S - Sale | $9.24 | -140 | 18,571 | -1% | -$1,294 | ||||||
| D | 2025-01-03 | ABOS | Acumen Pharmaceuticals, Inc. | Oconnell Daniel Joseph | CEO | S - Sale+OE | $1.84 | -47,778 | 680,107 | -7% | -$87,873 | |||||
| D | 2025-01-03 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale+OE | $1.84 | -11,122 | 164,545 | -6% | -$20,506 | |||||
| D | 2025-01-03 | ABOS | Acumen Pharmaceuticals, Inc. | Barton Russell | COO | S - Sale+OE | $1.86 | -7,636 | 139,031 | -5% | -$14,225 | |||||
| D | 2025-01-03 | ABOS | Acumen Pharmaceuticals, Inc. | Zuga Matt | CFO, Chief Business Officer | S - Sale+OE | $1.84 | -13,235 | 265,010 | -5% | -$24,367 | |||||
| D | 2025-01-03 | ABOS | Acumen Pharmaceuticals, Inc. | Siemers Eric | Chief Medical Officer | S - Sale+OE | $1.85 | -10,859 | 173,517 | -6% | -$20,047 | |||||
2025-01-03 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $45.59 | -144 | 113,027 | 0% | -$6,565 | ||||||
2025-01-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $45.59 | -229 | 274,466 | 0% | -$10,440 | ||||||
2025-01-03 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $45.59 | -160 | 133,273 | 0% | -$7,295 | ||||||
| D | 2025-01-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $45.59 | -546 | 672,518 | 0% | -$24,893 | |||||
| D | 2025-01-06 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale+OE | $4.31 | -1,056 | 125,646 | -1% | -$4,551 | |||||
2025-01-06 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $6.08 | -10,000 | 83,863 | -11% | -$60,800 | ||||||
2025-01-06 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $12.51 | -4,000 | 95,760 | -4% | -$50,040 | ||||||
| D | 2025-01-06 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $85.58 | -5,000 | 28,222 | -15% | -$427,923 | |||||
2025-01-06 | HALO | Halozyme Therapeutics, Inc. | Henderson Jeffrey William | Dir | S - Sale | $50.01 | -10,000 | 43,611 | -19% | -$500,060 | ||||||
| DM | 2025-01-03 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale+OE | $78.40 | -10,604 | 28,230 | -27% | -$831,379 | |||||
| DM | 2025-01-03 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $78.40 | -6,362 | 32,456 | -16% | -$498,796 | |||||
| DM | 2025-01-03 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $78.40 | -6,362 | 32,456 | -16% | -$498,796 | |||||
| DM | 2025-01-03 | ACLX | Arcellx, Inc. | Elghandour Rami | SEE REMARKS | S - Sale+OE | $78.40 | -28,633 | 149,176 | -16% | -$2,244,896 | |||||
2025-01-03 | SRZN | Surrozen, Inc./De | Li Yang | Exec. VP, Research | S - Sale | $17.37 | -843 | 13,345 | -6% | -$14,643 | ||||||
| M | 2025-01-02 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $4.27 | -80,909 | 308,754 | -21% | -$345,572 | |||||
2025-01-03 | SRZN | Surrozen, Inc./De | Williams Charles O | CFO, COO | S - Sale | $17.37 | -1,181 | 8,982 | -12% | -$20,514 | ||||||
2025-01-02 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $24.68 | -1,241 | 102,968 | -1% | -$30,628 | ||||||
2025-01-02 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $24.68 | -1,117 | 43,814 | -2% | -$27,568 | ||||||
2025-01-06 | KYMR | Kymera Therapeutics, Inc. | Chiniara Ellen | GC | S - Sale | $41.75 | -3,129 | 54,826 | -5% | -$130,645 | ||||||
| D | 2025-01-02 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $46.94 | -4,085 | 255,348 | -2% | -$191,740 | |||||
| D | 2025-01-02 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale+OE | $83.66 | -8,000 | 205,695 | -4% | -$669,267 | |||||
| D | 2025-01-02 | ATHA | Athira Pharma, Inc. | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $0.56 | -10,826 | 35,841 | -23% | -$6,083 | |||||
| D | 2025-01-02 | ATHA | Athira Pharma, Inc. | Litton Mark James | Pres, CEO | S - Sale+OE | $0.56 | -25,107 | 262,280 | -9% | -$14,108 | |||||
| D | 2025-01-02 | ATHA | Athira Pharma, Inc. | Church Kevin | Chief Scientific Officer | S - Sale+OE | $0.56 | -8,510 | 130,761 | -6% | -$4,782 | |||||
| D | 2025-01-02 | ATHA | Athira Pharma, Inc. | Renninger Robert | VP of Finance | S - Sale+OE | $0.56 | -2,881 | 89,724 | -3% | -$1,619 | |||||
| D | 2025-01-02 | ATHA | Athira Pharma, Inc. | Worthington Mark | GC, CCO | S - Sale+OE | $0.56 | -8,510 | 83,735 | -9% | -$4,782 | |||||
| D | 2024-12-31 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $138.10 | -272 | 2,507 | -10% | -$37,563 | |||||
2024-12-31 | DNLI | Denali Therapeutics Inc. | Krognes Steve E. | Dir | S - Sale | $20.25 | -30,000 | 810,893 | -4% | -$607,500 | ||||||
2025-01-02 | DNLI | Denali Therapeutics Inc. | Sato Vicki L | Dir | S - Sale | $20.91 | -3,080 | 107,976 | -3% | -$64,403 | ||||||
| D | 2024-12-30 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | P - Purchase | $0.00 | +38,974,101 | 38,974,101 | New | +$0 | |||||
2024-12-13 | NVAX | Novavax Inc | King Rachel K. | Dir | S - Sale | $9.02 | -4,150 | 14,770 | -22% | -$37,435 | ||||||
| M | 2024-12-24 | NVAX | Novavax Inc | Young James F | Dir | S - Sale | $8.22 | -10,000 | 51,760 | -16% | -$82,208 | |||||
2024-12-30 | DTIL | Precision Biosciences Inc | Germano Geno J | Dir | P - Purchase | $4.49 | +3,605 | 7,807 | +86% | +$16,186 | ||||||
| M | 2024-12-27 | IVVD | Invivyd, Inc. | McGuire Terrance | Dir | S - Sale | $0.48 | -273,763 | 6,797,997 | -4% | -$131,529 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |